MBX Biosciences, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by Hawryluk P. Kent, was filed 16 Mar 2026.
Who traded when
BuySale+1 other insider
Since the insiders bought
- +83.3%Entry US$29.74 · Close 12 Nov 2026 US$54.51
- +256.0%Entry US$15.31 · Close 12 Nov 2026 US$54.51
- +215.9%Entry US$17.90 · Close at T+365 US$56.55
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate MBX Biosciences, Inc. Strong Buy (bullish), based on 10 analysts. Average price target: US$95.70.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
T+90 is the date 90 days after the filing, the exit horizon used to measure each purchase.
- 4,893 shares@ US$54.820.0098% mcap33.9% of flowCommon StockSEC:0001193125-26-457015:0
- 4,893 shares@ US$54.82290.0098% mcap51.3% of flowCommonSEC144:0001959173-26-007930
- 373 shares@ US$53.960.0008% mcap22.9% of flowCommon StockSEC:0001193125-26-449832:0
- 373 shares@ US$53.95920.0008% mcap29.7% of flowCommonSEC144:0001959173-26-007744
- 3,745 shares@ US$68.28760.0092% mcap9.3% of flowCommonSEC144:0001959173-26-006112
- 370 shares@ US$65.770.0009% mcap27.1% of flowCommon StockSEC:0001193125-26-335373:0
- 370 shares@ US$65.77290.0009% mcap27.1% of flowCommonSEC144:0001959173-26-005628
- 936 shares@ US$65.77290.0023% mcap2.2% of flowCommonSEC144:0001959173-26-005629
- 28,000 shares0Common StockSEC:0001193125-26-331642:0
- 71,000 shares0Common StockSEC:0001193125-26-331639:0
- 9,167 shares@ US$30.54540.0095% mcap46.6% of flowCommonSEC144:0001959173-26-004511
- 10,833 shares@ US$29.65690.011% mcap53.4% of flowCommonSEC144:0001959173-26-004487
- 18,500 shares@ US$28.414219.1% of flowCommon StockSEC:0001193125-26-107268:0Canonical exit: 11 Jun 2026 (T+90)
- 28,768 shares@ US$16.0016.3% of flowCommon StockSEC:0001193125-26-082562:0
- 15,000 shares0Common StockSEC:0001193125-26-035584:0
- 35,250 shares0Common StockSEC:0001193125-26-035582:0
- 15,000 shares0Common StockSEC:0001193125-26-035587:0
- 182,859 shares@ US$3.2521.5% of flowCommon StockSEC:0001193125-25-252404:0
- 20,000 shares@ US$13.63959.8% of flowCommon StockSEC:0001193125-25-245411:0Canonical exit: 18 Jan 2026 (T+90)
- 20,000 shares@ US$13.2492100.0% of flowCommon StockSEC:0001193125-25-243653:0Canonical exit: 15 Jan 2026 (T+90)
- 666,666 shares@ US$18.00100.0% of flowCommon StockSEC:0001231919-25-000267:0Canonical exit: 25 Dec 2025 (T+90)
- 7,693 shares@ US$5.89100.0% of flowCommon StockSEC:0000950170-25-052685:0Canonical exit: 7 Jul 2025 (T+90)
- 29,540 shares@ US$9.852.2% of flowCommon StockSEC:0000947871-25-000200:1Canonical exit: 15 May 2025 (T+90)
- 49,070 shares@ US$10.844.0% of flowCommon StockSEC:0000947871-25-000200:2Canonical exit: 19 May 2025 (T+90)
- 94,100 shares@ US$10.847.7% of flowCommon StockSEC:0000947871-25-000200:3Canonical exit: 19 May 2025 (T+90)
25 of 80 declarations
About MBX Biosciences, Inc.
MBX Biosciences, Inc. (XNAS, Health Care, market capitalisation of 2,712,858,368 USD) has 62 filings, 36 of them in 2024, 10 in 2025 and 16 in 2026, covering trades from September 16, 2024 to November 10, 2026. Purchases weigh heavily: 14 purchases worth EUR 44,242,534, with a median of EUR 512,426, against 2 sales worth EUR 39,003, or 88% of market trades. The pack flags 10 cluster-buy filings.
On September 16, 2024, four filers bought for EUR 30,549,340, including Tiba Aynechi (Director) for EUR 10,782,120 and Frazier Life Sciences X, L.P., a 10% owner, for EUR 8,985,100. Patrick J. Heron (Director) bought EUR 10,289,150 on September 26, 2025. P. Kent Hawryluk (President & CEO) has 8 filings, 3 of them purchases; Orbimed Advisors LLC (Director) has 6, 4 of them purchases.
Read moreShow less
The two sales are Salomon Azoulay's (Chief Medical Officer): EUR 21,132 on August 4, 2026 and EUR 17,871 on November 4, 2026. Over twelve months: 16 filings, one purchase, 2 sales. For 14 purchases, the median 90-day result is 3.6%, with 64% positive: stored past results, not a forecast.
Written on 12 November 2026 from the filings and market data available that day. Live figures are in the blocks above.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendationsThe weekly insider digest, free
One email on Fridays: the insider clusters and single-name signals worth reading. Unsubscribe in one click.
